TXMD - Therapeutics MD GAAP EPS of -$3.13 misses by $1.09 revenue of $20.92M misses by $9.28M
- Therapeutics MD press release ( NASDAQ: TXMD ): Q3 GAAP EPS of -$3.13 misses by $1.09 .
- Revenue of $20.92M (-17.7% Y/Y) misses by $9.28M .
- As of September 30, 2022, the Company’s cash on hand totaled $27.1 million, compared with $65.1 million as of December 31, 2021.
- As of September 30, 2022, the Company’s aggregate balance of net debt, lender warrants derivative liability, make-whole payment derivative liability and mandatory redeemable preferred stock was $117.1 million.
- Shares -10.06% AH.
For further details see:
Therapeutics MD GAAP EPS of -$3.13 misses by $1.09, revenue of $20.92M misses by $9.28M